Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Total Liabilities (2022 - 2025)

Axsome Therapeutics' Total Liabilities history spans 4 years, with the latest figure at $601.5 million for Q4 2025.

  • For Q4 2025, Total Liabilities rose 17.6% year-over-year to $601.5 million; the TTM value through Dec 2025 reached $601.5 million, up 17.6%, while the annual FY2025 figure was $601.5 million, 17.6% up from the prior year.
  • Total Liabilities for Q4 2025 was $601.5 million at Axsome Therapeutics, up from $595.5 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $601.5 million in Q4 2025 and bottomed at $73.9 million in Q1 2022.
  • The 4-year median for Total Liabilities is $399.5 million (2023), against an average of $382.2 million.
  • The largest annual shift saw Total Liabilities skyrocketed 275.52% in 2023 before it increased 17.6% in 2025.
  • A 4-year view of Total Liabilities shows it stood at $221.9 million in 2022, then surged by 79.01% to $397.3 million in 2023, then rose by 28.75% to $511.5 million in 2024, then rose by 17.6% to $601.5 million in 2025.
  • Per Business Quant, the three most recent readings for AXSM's Total Liabilities are $601.5 million (Q4 2025), $595.5 million (Q3 2025), and $566.7 million (Q2 2025).